Bristol Myers pitches in to Pathios’ $25M Series B for GPCR inhibitorGPCR inhibitor
18 Apr 2024
Pathios Therapeutics drew in $25 million for the first close of a Series B raise that should help the UK biotech test its first-in-class solid tumor candidate in clinical trials by the end of the year.
The raise will also be used to expand Pathios, including its executive team, “to align with its continued evolution,” the company said Thursday. The biotech was founded in 2017 by Tom McCarthy and Alan Naylor. It has approximately 20 staffers, a spokesperson said.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.